A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group Study

L. M. Morrell, Bach Ardalan, Stephen P Richman, P. Goodman, T. R. Fleming, J. S. MacDonald

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to potentiate 5-fluorouracil (5-FU), has been shown to have synergy in vivo and in vitro. Twenty-seven patients were treated with an intravenous push dose of PALA (250 mg/m2) followed 24 hours later with a 24-hour infusion of 5-FU (2600 mg/m2). This regimen was repeated weekly. There was one partial response of 21 eligible patients with an estimated response rate of 5%. Toxicity was severe with one toxic death and four patients experiencing Grade 4 toxicity. 5-Fluorouracil and PALA, given in the schedule described, do not appear to be effective against adenocarcinoma of the pancreas.

Original languageEnglish
Pages (from-to)363-366
Number of pages4
JournalCancer
Volume67
Issue number2
DOIs
StatePublished - Feb 11 1991

Fingerprint

NSC 224131
Fluorouracil
Pancreas
Adenocarcinoma
Poisons
Appointments and Schedules
Therapeutics
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{deba3a24469443bca0dc3af9e897f699,
title = "A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group Study",
abstract = "Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to potentiate 5-fluorouracil (5-FU), has been shown to have synergy in vivo and in vitro. Twenty-seven patients were treated with an intravenous push dose of PALA (250 mg/m2) followed 24 hours later with a 24-hour infusion of 5-FU (2600 mg/m2). This regimen was repeated weekly. There was one partial response of 21 eligible patients with an estimated response rate of 5{\%}. Toxicity was severe with one toxic death and four patients experiencing Grade 4 toxicity. 5-Fluorouracil and PALA, given in the schedule described, do not appear to be effective against adenocarcinoma of the pancreas.",
author = "Morrell, {L. M.} and Bach Ardalan and Richman, {Stephen P} and P. Goodman and Fleming, {T. R.} and MacDonald, {J. S.}",
year = "1991",
month = "2",
day = "11",
doi = "10.1002/1097-0142(19910115)67:2<363::AID-CNCR2820670208>3.0.CO;2-H",
language = "English",
volume = "67",
pages = "363--366",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group Study

AU - Morrell, L. M.

AU - Ardalan, Bach

AU - Richman, Stephen P

AU - Goodman, P.

AU - Fleming, T. R.

AU - MacDonald, J. S.

PY - 1991/2/11

Y1 - 1991/2/11

N2 - Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to potentiate 5-fluorouracil (5-FU), has been shown to have synergy in vivo and in vitro. Twenty-seven patients were treated with an intravenous push dose of PALA (250 mg/m2) followed 24 hours later with a 24-hour infusion of 5-FU (2600 mg/m2). This regimen was repeated weekly. There was one partial response of 21 eligible patients with an estimated response rate of 5%. Toxicity was severe with one toxic death and four patients experiencing Grade 4 toxicity. 5-Fluorouracil and PALA, given in the schedule described, do not appear to be effective against adenocarcinoma of the pancreas.

AB - Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to potentiate 5-fluorouracil (5-FU), has been shown to have synergy in vivo and in vitro. Twenty-seven patients were treated with an intravenous push dose of PALA (250 mg/m2) followed 24 hours later with a 24-hour infusion of 5-FU (2600 mg/m2). This regimen was repeated weekly. There was one partial response of 21 eligible patients with an estimated response rate of 5%. Toxicity was severe with one toxic death and four patients experiencing Grade 4 toxicity. 5-Fluorouracil and PALA, given in the schedule described, do not appear to be effective against adenocarcinoma of the pancreas.

UR - http://www.scopus.com/inward/record.url?scp=0025962951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025962951&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19910115)67:2<363::AID-CNCR2820670208>3.0.CO;2-H

DO - 10.1002/1097-0142(19910115)67:2<363::AID-CNCR2820670208>3.0.CO;2-H

M3 - Article

C2 - 1985731

AN - SCOPUS:0025962951

VL - 67

SP - 363

EP - 366

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -